Figure 2.

A Paradigm of 3 i.c.v. ASO Injections Reduces Atxn1 throughout the CNS

(A) 500 μg Atxn1-targeting ASO353 or non-targeting ASO was delivered by 3 bolus i.c.v. injections to Atxn1^2Q/2Q mice at 5, 13, and 21 weeks of age. At 26 weeks, mice were sacrificed for analyses. (B) Rt qPCR analysis of Atxn1 expression in the cerebral cortex, cerebellum, and medulla of Atxn1^2Q/2Q mice given either no treatment (n = 4), non-targeting ASO (n = 4), or Atxn1-targeting ASO353 (n = 4). ∗∗p < 0.01; ∗∗∗p < 0.001.